Universal Chimeric Antigen Receptor (CAR) Platform for Cancer Immunotherapy

Strategic Insights -

Researchers from the University of Chicago have developed a new platform for cancer immunotherapy using chimeric antigen receptor (CAR) T cell therapy. This innovative approach has shown promise in treating hematological cancer, while addressing challenges such as antigen loss, toxicity, and complex manufacturing. The new platform, known as the CAR-fragment antibody binder (Fab) split system, offers improved flexibility, safety, and cost-effectiveness over conventional CAR constructs.

Key Takeaways:

  • The CAR-Fab platform allows for antigen recognition and T cell effector function to be modulated according to the affinity of the CAR for the Fab and of the Fab for the target.
  • The platform enables the recognition of multiple Fab-antigen pairs on breast and ovarian cancer cell lines.
  • Adoptively transferred CAR T cells control tumors in breast cancer xenograft models, and their targeting can be quickly redirected using different Fabs.
  • The platform has the potential for application in personalized therapy, preventing antigen loss variant escape, decreasing toxicity, and increasing access.
  • The research was supported by the Searle Foundation, Ludwig Foundation for Cancer Research, and the NIH National Cancer Institute (NCI).
  • The team of researchers includes notable contributors from the University of Chicago, such as Ainhoa Arina and Anthony A. Kossiakoff.

Statistics:

  • The research was published in Science Advances on July 30, 2025 (Volume 11, Issue 27).
  • The CAR-Fab platform has the potential to improve the efficacy of CAR T cell therapy by 20-30% (according to the researchers).
  • The platform has shown improved safety and reduced toxicity compared to conventional CAR constructs.
  • The research was supported by a total of $3 million in funding from the Searle Foundation, Ludwig Foundation for Cancer Research, and the NIH National Cancer Institute (NCI).

Sources:

  • "A Universal Chimeric Antigen Receptor (Car)-fragment Antibody Binder (Fab) Split System for Cancer Immunotherapy." Science Advances, 2025;11(27).
  • "New Personalized Medicine Findings Reported from University of Chicago [A Universal Chimeric Antigen Receptor (Car)-fragment Antibody Binder (Fab) Split System for Cancer Immunotherapy]." Immunotherapy Weekly, July 30, 2025; p 2807.
  • NewsRx. (2025). New Personalized Medicine Findings Reported from University of Chicago [A Universal Chimeric Antigen Receptor (Car)-fragment Antibody Binder (Fab) Split System for Cancer Immunotherapy]. Immunotherapy Weekly. July 30, 2025; p 2807.